ADALIMUMAB, INFLIXIMAB AND ETANERCEPT BIOSIMILARS MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST

  2024-11-27 |   Pages: 200+ |   Report ID: MD-R-2024-11-27-148227 |   Pharmaceuticals and Healthcare

Historical data: 2018 - 2023

Forecast period: 2024 - 2031

Quantitative units: Revenue in USD million and CAGR from 2024 to 2031

Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Adalimumab, Infliximab And Etanercept Biosimilars Market

Image

1.1 SCOPE OF THE REPORT

1.2 MARKET SEGMENT ANALYSIS

1.3 REGULATORY SCENARIO BY REGION/COUNTRY

1.4 MARKET INVESTMENT SCENARIO STRATEGIC

1.5 MARKET ANALYSIS BY TYPE (USD MILLION)

1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)

2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS

  2.1.1 MARKET DRIVER ANALYSIS

  2.1.2 MARKET RESTRAINT ANALYSIS

  2.1.3 MARKET OPPORTUNITY

  2.1.4 MARKET CHALLENGES

3.1 INDUSTRY TRENDS

  3.1.1 SWOT ANALYSIS

  3.1.2 PESTEL ANALYSIS

  3.1.3 PORTER’S FIVE FORCES ANALYSIS

3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS

4.1 COVID-19 ANALYSIS

5.1 GLOBAL ADALIMUMAB, INFLIXIMAB AND ETANERCEPT BIOSIMILARS MARKET, SALES AREA, TYPE

5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL ADALIMUMAB, INFLIXIMAB AND ETANERCEPT BIOSIMILARS MARKET

7.1 GLOBAL ADALIMUMAB, INFLIXIMAB AND ETANERCEPT BIOSIMILARS MARKET SIZE AND SHARE (2018-2031) (USD MILLION)

8.1 GLOBAL ADALIMUMAB, INFLIXIMAB AND ETANERCEPT BIOSIMILARS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

8.2 GLOBAL ADALIMUMAB, INFLIXIMAB AND ETANERCEPT BIOSIMILARS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

9.1 GLOBAL ADALIMUMAB, INFLIXIMAB AND ETANERCEPT BIOSIMILARS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

9.2 GLOBAL ADALIMUMAB, INFLIXIMAB AND ETANERCEPT BIOSIMILARS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

10.1 GLOBAL ADALIMUMAB, INFLIXIMAB AND ETANERCEPT BIOSIMILARS MARKET SIZE AND SHARE BY REGION (2018-2023) (USD MILLION)

10.2 GLOBAL ADALIMUMAB, INFLIXIMAB AND ETANERCEPT BIOSIMILARS MARKET SIZE AND SHARE BY REGION (2024-2031) (USD MILLION)

11.1 NORTH AMERICA ADALIMUMAB, INFLIXIMAB AND ETANERCEPT BIOSIMILARS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

11.2 NORTH AMERICA ADALIMUMAB, INFLIXIMAB AND ETANERCEPT BIOSIMILARS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

11.3 NORTH AMERICA ADALIMUMAB, INFLIXIMAB AND ETANERCEPT BIOSIMILARS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

11.4 NORTH AMERICA ADALIMUMAB, INFLIXIMAB AND ETANERCEPT BIOSIMILARS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

11.5 NORTH AMERICA ADALIMUMAB, INFLIXIMAB AND ETANERCEPT BIOSIMILARS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

11.6 NORTH AMERICA ADALIMUMAB, INFLIXIMAB AND ETANERCEPT BIOSIMILARS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

12.1 EUROPE ADALIMUMAB, INFLIXIMAB AND ETANERCEPT BIOSIMILARS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

12.2 EUROPE ADALIMUMAB, INFLIXIMAB AND ETANERCEPT BIOSIMILARS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

12.3 EUROPE ADALIMUMAB, INFLIXIMAB AND ETANERCEPT BIOSIMILARS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

12.4 EUROPE ADALIMUMAB, INFLIXIMAB AND ETANERCEPT BIOSIMILARS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

12.5 EUROPE ADALIMUMAB, INFLIXIMAB AND ETANERCEPT BIOSIMILARS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

12.6 EUROPE ADALIMUMAB, INFLIXIMAB AND ETANERCEPT BIOSIMILARS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

13.1 ASIA PACIFIC ADALIMUMAB, INFLIXIMAB AND ETANERCEPT BIOSIMILARS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

13.2 ASIA PACIFIC ADALIMUMAB, INFLIXIMAB AND ETANERCEPT BIOSIMILARS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

13.3 ASIA PACIFIC ADALIMUMAB, INFLIXIMAB AND ETANERCEPT BIOSIMILARS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

13.4 ASIA PACIFIC ADALIMUMAB, INFLIXIMAB AND ETANERCEPT BIOSIMILARS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

13.5 ASIA PACIFIC ADALIMUMAB, INFLIXIMAB AND ETANERCEPT BIOSIMILARS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

13.6 ASIA PACIFIC ADALIMUMAB, INFLIXIMAB AND ETANERCEPT BIOSIMILARS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

14.1 LATIN AMERICA ADALIMUMAB, INFLIXIMAB AND ETANERCEPT BIOSIMILARS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)/p>

14.2 LATIN AMERICA ADALIMUMAB, INFLIXIMAB AND ETANERCEPT BIOSIMILARS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

14.3 LATIN AMERICA ADALIMUMAB, INFLIXIMAB AND ETANERCEPT BIOSIMILARS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

14.4 LATIN AMERICA ADALIMUMAB, INFLIXIMAB AND ETANERCEPT BIOSIMILARS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

14.5 LATIN AMERICA ADALIMUMAB, INFLIXIMAB AND ETANERCEPT BIOSIMILARS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

14.6 LATIN AMERICA ADALIMUMAB, INFLIXIMAB AND ETANERCEPT BIOSIMILARS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

15.1 MIDDLE EAST & AFRICA ADALIMUMAB, INFLIXIMAB AND ETANERCEPT BIOSIMILARS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

15.2 MIDDLE EAST & AFRICA ADALIMUMAB, INFLIXIMAB AND ETANERCEPT BIOSIMILARS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

15.3 MIDDLE EAST & AFRICA ADALIMUMAB, INFLIXIMAB AND ETANERCEPT BIOSIMILARS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

15.4 MIDDLE EAST & AFRICA ADALIMUMAB, INFLIXIMAB AND ETANERCEPT BIOSIMILARS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

15.5 MIDDLE EAST & AFRICA ADALIMUMAB, INFLIXIMAB AND ETANERCEPT BIOSIMILARS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

15.6 MIDDLE EAST & AFRICA ADALIMUMAB, INFLIXIMAB AND ETANERCEPT BIOSIMILARS MARKET SIZE AND SHARE BY APPLICATION (2024-2031)< (USD MILLION)/p>

16.1 Boehringer Ingelheim

  16.1.1 COMPANY DETAILS

  16.1.2 FINANCIALS (USD MILLION)

  16.1.3 PRODUCT SUMMARY

  16.1.4 RECENT DEVELOPMENTS

16.2 Abbvie

16.3 Cipla Ltd

16.4 Hetero Drugs Limited

16.5 Pfizer

16.6 Novartis

16.7 Samsung Bioepis(Samsung Biologics)

16.8 Amgen

16.9 Celltrion Healthcare

16.10 Mylan

16.11 HETERO

16.12 Glenmark Pharmaceuticals

16.13 Emcure Pharmaceuticals

18.1 METHODOLOGY

18.2 RESEARCH DATA SOURCE

  18.2.1 SECONDARY DATA

  18.2.2 KEY DATA FROM SECONDARY

  18.2.3 PRIMARY DATA

  18.2.4 KEY DATA FROM PRIMARY

  18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS

  18.2.6 MARKET ESTIMATION

  18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH

  18.2.8 LEGAL DISCLAIMER

Market Segments

By Type

Adalimumab Biosimilars
Infliximab Biosimilars
Etanercept Biosimilars

By Application

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Companies

Boehringer Ingelheim
Abbvie
Cipla Ltd
Hetero Drugs Limited
Pfizer
Novartis
Samsung Bioepis(Samsung Biologics)
Amgen
Celltrion Healthcare
Mylan
HETERO
Glenmark Pharmaceuticals
Emcure Pharmaceuticals

Single User License  : 3900$
Corporate License    : 7800$
Enquiry Before Buying
Request For Customization
Speak To Analyst

BROWSE INDUSTRY

  1. Consumer Goods
  2. Healthcare
  3. Food & Beverage
  4. Heavy Industry
  5. Service Industries
  6. FMCG
  7. Life Sciences
  8. Technology & Media
  9. Machinery & Equipment

    WHY CHOOSE US

  •   PROACTIVE

    • We manage our resources 24/7 to identify issues and address them before they become problems.

  •   QUALITY & RELIABILITY

    • We are committed to providing reliable and highly accurate data with an excellent quality control system.

  •   GLOBAL OUTREACH

    • 6 Major regions and 40+ countries level analysis accomplished.

  •   COMPETITIVE PRICING

    • Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.